Literature DB >> 24552449

A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in primigravidae.

M R Zainul Rashid1, Jing Fen Lim, Noorfaizahtul Hanim M Nawawi, Melissha Luqman, Muhammad Faizuddin Zolkeplai, Harry Surya Rangkuty, Natasha Ain Mohamad Nor, Azmi Tamil, Shamsul Azhar Shah, Seong Wai Tham, A E Schindler.   

Abstract

BACKGROUND: Gestational hypertension (GH) remains one of the main causes of high maternal and perinatal morbidity and mortality worldwide with the highest incidence among primigravidae of about 10%-15%. However, it was noted that the incidence of GH in primigravidae who conceived following assisted reproductive technique (ART) or intrauterine insemination (IUI) supplemented with dydrogesterone during the first trimester was low. AIM: To determine whether dydrogesterone supplementation during the first trimester can reduce the incidence of GH among primigravidae.
METHOD: A prospective cross-sectional comparative study was undertaken in 2010 on 116 primigravidae (study group) who conceived following ART or IUI and supplemented with dydrogesterone up to 16 weeks gestation. They were matched for age and race at 16 weeks gestation with a control patient from the early pregnancy clinic who were primigravidae (n = 116) who conceived spontaneously without dydrogesterone supplementation.
FINDINGS: The incidence of GH in the study group was significantly lower than the control group (1.7% versus 12.9%, p = 0.001). The incidence of fetal distress was also significantly lower in the study group compared to the control group (4.3% versus 18.1%, p = 0.001).
INTERPRETATION: Dydrogesterone supplementation during the first trimester significantly reduced the incidence of GH and fetal distress in primigravidae.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24552449     DOI: 10.3109/09513590.2013.860960

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

1.  Combination treatment of captopril and prazosin to treat patients with gestational hypertension.

Authors:  Bo Hong; Xiang Ding; Hongmei Iia; Jianmei Zhang
Journal:  Exp Ther Med       Date:  2018-08-13       Impact factor: 2.447

2.  Effect of dydrogesterone and progesterone on threatened miscarriage due to corpus luteum insufficiency.

Authors:  Caiyu Lou; Caiwen Wang; Qiang Zhao; Fenyuan Jin
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Candesartan targeting of angiotensin II type 1 receptor demonstrates benefits for hypertension in pregnancy via the NF‑κB signaling pathway.

Authors:  Xudong Zhao; Xietong Wang
Journal:  Mol Med Rep       Date:  2018-05-23       Impact factor: 2.952

4.  Pregnancy-related complications and perinatal outcomes following progesterone supplementation before 20 weeks of pregnancy in spontaneously achieved singleton pregnancies: a systematic review and meta-analysis.

Authors:  Hanglin Wu; Songying Zhang; Xiaona Lin; Jing He; Shasha Wang; Ping Zhou
Journal:  Reprod Biol Endocrinol       Date:  2021-11-04       Impact factor: 5.211

5.  Comparison of oral dydrogesterone with vaginal progesteronefor luteal support in IUI cycles: a randomized clinical trial.

Authors:  Donya Khosravi; Robabeh Taheripanah; Anahita Taheripanah; Vahid Tarighat Monfared; Seyed-Mostafa Hosseini-Zijoud
Journal:  Iran J Reprod Med       Date:  2015-07

6.  Progesterone Attenuates SIRT1-Deficiency-Mediated Pre-Eclampsia.

Authors:  Jiangnan Pei; Zhenzhen Liu; Chengjie Wang; Nan Chu; Lei Liu; Yao Tang; Haiyan Liu; Qianqian Xiang; Haidong Cheng; Mingqing Li; Weirong Gu
Journal:  Biomolecules       Date:  2022-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.